Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma

Virchows Archiv

Volumn 465, Issue 2, 2014, Pages 145-154

  Yoshida, Hiroshi ^a,c   Yamamoto, Noriko ^b   Taniguchi, Hirokazu ^a   Oda, Ichiro ^a   Katai, Hitoshi ^a   Kushima, Ryoji ^a   Tsuda, Hitoshi ^a,d  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b CANCER INSTITUTE   (Japan)

^c ASAHI GENERAL HOSPITAL   (Japan)

^d NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Fluorescence in situ hybridization; Gastric cancer; HER2; Immunohistochemistry; Polysomy 17

Indexed keywords

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BIOPSY; DIGESTIVE SYSTEM SURGICAL PROCEDURES; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC HETEROGENEITY; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84905982126     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-014-1597-3     Document Type: Article

References (50)

1. Krejs GJ (2010) Gastric cancer: epidemiology and risk factors. Dig Dis 28(4-5):600-603
2. Scartozzi M et al (2010) Novel perspectives for the treatment of gastric cancer: from a global approach to a personalized strategy. Curr Oncol Rep 12(3):175-185
3. Bang YJ et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687-697
4. Urano N et al (2006) Overexpression of hypoxia-inducible factor-1 alpha in gastric adenocarcinoma. Gastric Cancer 9(1):44-49
5. Sakai K et al (1986) Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas. J Natl Cancer Inst 77(5):1047-1052 (Pubitemid 17184126)
6. Ishida T et al (1994) Significance of erbB-2 gene product as a target molecule for cancer therapy. Scand J Immunol 39(5):459-466 (Pubitemid 24227769)
7. Tokunaga A et al (1995) Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer. Cancer 75(6 Suppl):1418-1425
8. Yano T et al (2006) Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 15(1):65-71
9. Yokota J et al (1988) Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. Oncogene 2(3):283-287 (Pubitemid 18085309)
10. Kim JW et al (2012) The prognostic significance of HER2 positivity for advanced gastric cancer patients undergoing first-line modified FOLFOX-6 regimen. Anticancer Res 32(4):1547-1553
11. Shitara K et al (2013) Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment. Gastric Cancer 16(2):261-267
12. Tanner M et al (2005) Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16(2):273-278 (Pubitemid 40309309)
13. Terashima M et al (2012) Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res 18(21):5992-6000
14. Kim MA et al (2007) Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Hum Pathol 38(9):1386-1393 (Pubitemid 47247482)
15. Matsubara J et al (2008) Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer. Clin Cancer Res 14(10):3022-3029
16. Yan B et al (2010) A study of HER2 gene amplification and protein expression in gastric cancer. J Clin Pathol 63(9):839-842
17. Yan SY et al (2011) Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma. World J Gastroenterol 17(11):1501-1506
18. Lee S et al (2011) Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections. Histopathology 59(5):832-840
19. Liu W et al (2012) HER-2/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients. J Clin Gastroenterol 46(4):e31-e37
20. Giuffre G et al (2012) HER2 status in unusual histological variants of gastric adenocarcinomas. J Clin Pathol 65(3):237-241
21. Tsapralis D et al (2012) Human epidermal growth factor receptor-2 gene amplification in gastric cancer using tissue microarray technology. World J Gastroenterol 18(2):150-155
22. Halon A et al (2012) HER-2 expression in immunohistochemistry has no prognostic significance in gastric cancer patients. Sci World J 2012:941259
23. Uchino S et al (1993) Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients. Cancer 72(11):3179-3184 (Pubitemid 23356757)
24. Dang HZ, Yu Y, Jiao SC (2012) Prognosis of HER2 over-expressing gastric cancer patients with liver metastasis. World J Gastroenterol 18(19):2402-2407
25. Jorgensen JT, Hersom M (2012) HER2 as a prognostic marker in gastric cancer - a systematic analysis of data from the literature. J Cancer 3:137-144
26. Park DI et al (2006) HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 51(8):1371-1379 (Pubitemid 44315804)
27. Gomez-Martin C et al (2012) HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer. J Clin Pathol 65(8):751-757
28. Janjigian YY et al (2012) Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol 23(10):2656-2662
29. Kimura M et al (2004) A proposal for diagnostically meaningful criteria to classify increased epidermal growth factor receptor and c-erbB-2 gene copy numbers in gastric carcinoma, based on correlation of fluorescence in situ hybridization and immunohistochemical measurements. Virchows Arch 445(3):255-262 (Pubitemid 39286893)
30. Park YS et al (2012) Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use? Hum Pathol 43(3):413-422
31. Hofmann M et al (2008) Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52(7):797-805 (Pubitemid 351724903)
32. Grabsch H et al (2010) HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. Cell Oncol 32(1-2):57-65
33. Kunz PL et al (2012) HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Appl Immunohistochem Mol Morphol 20(1):13-24
34. Ruschoff J et al (2010) HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 457(3):299-307
35. Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33(1):159-174 (Pubitemid 8054849)
36. Tafe LJ et al (2011) Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization. Arch Pathol Lab Med 135(11):1460-1465
37. Garcia I et al (2003) Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol 10(3):234-241 (Pubitemid 40486955)
38. Jaehne J et al (1992) Expression of Her2/neu oncogene product p185 in correlation to clinicopathological and prognostic factors of gastric carcinoma. J Cancer Res Clin Oncol 118(6):474-479
39. Im SA et al (2011) Clinicopathologic characteristics of patients with stage III/IV (M(0)) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization. Diagn Mol Pathol 20(2):94-100
40. Kim KC et al (2011) Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann Surg Oncol 18(10):2833-2840
41. Tsuda H et al (2001) Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression. Cancer 92(12):2965-2974 (Pubitemid 33136190)
42. Yang J et al (2012) Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens. Cell Biochem Biophys 62(1):221-228
43. Yan B et al (2011) Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples. J Clin Pathol 64(10):880-883
44. Ruschoff J et al (2012) HER2 testing in gastric cancer: a practical approach. Mod Pathol 25(5):637-650
45. Warneke VS et al (2013) Her2/neu testing in gastric cancer: evaluating the risk of sampling errors. Ann Oncol 24(3):725-733
46. Guarneri V et al (2008) Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management. Oncologist 13(8):838-844
47. Pusztai L et al (2010) Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. Oncologist 15(11):1164-1168
48. Wolff AC et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31):3997-4013
49. Bozzetti C et al (2011) Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br J Cancer 104(9):1372-1376
50. Fassan M et al (2012) Human epithelial growth factor receptor 2 (HER2) status in primary and metastatic esophagogastric junction adenocarcinomas. Hum Pathol 43(8):1206-1212